Trusted Government Contractor and HPC Solution Provider Koi Computers Successfully Recertified to ISO 9001:2015
"We are proud to once again receive this ISO 9001 recertification, which reflects our ongoing commitment to continuous improvement and customer satisfaction," said Catherine Ho, Vice President of Federal Business Development at Koi Computers. "This achievement demonstrates the hard work and dedication of our entire team in upholding the highest quality standards."
ISO 9001 is a globally recognized standard for quality management systems. It provides a framework that organizations can follow to ensure they consistently meet customer expectations and improve performance. By implementing ISO 9001, organizations can increase their operational efficiency, improve customer satisfaction, and demonstrate their commitment to quality. As a result of Koi Computers' ISO 9001:2015 recertification, the federal government can continue to have confidence in the company's commitment to customer satisfaction and that effective quality controls are in place.
About Koi Computers
Headquartered in Greater Chicago since 1995, Koi Computers has been working with top technology manufacturers to deliver scalable high performance computing and technology solutions that improve efficiency, reliability and speed. The company's world-class engineering team specializes in building custom IT solutions that accommodate today's needs and tomorrow's vision with services that include performance benchmarking and outstanding support. Koi Computers has a strong track record of developing, building and deploying HPC technology for the U.S. Federal Government with satisfactory ratings in CPARS and Past Performance. The company is a Prime Contract Holder of the GSA IT Schedule 70, NASA SEWP V, and NITAAC CIO-CS contracts and the 2nd Generation Information Technology Blanket Purchase Agreement (2GIT BPA). To learn more, call: 888-LOVE-KOI (888-568-3564); email: sales@koicomputers.com or visit https://www.koicomputers.com.
For media inquiries, contact Catherine Ho at catherine@koicomputers.com (630) 627-8811.
Media Room, visit: https://www.koicomputers.com/about-us/mediaroom/
View original content to download multimedia:https://www.prnewswire.com/news-releases/trusted-government-contractor-and-hpc-solution-provider-koi-computers-successfully-recertified-to-iso-90012015-302365051.html
SOURCE Koi Computers, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025
SHANGHAI and HONG KONG, July 27, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for cancer, today announced that an abstract featuring the latest data from a Phase I/II study of the Claudin 18.2 antibody-drug conjugate (ADC), ATG-022, has been accepted for poster presentation at the 2025 European Society for Medical Oncology Annual Congress (ESMO 2025), taking place from October 17th to October 21st at the Messe Berlin in Berlin, Germany. Details of the Poster Presentation: ATG-022 (Claudin 18.2 antibody-drug conjugate)Title: Phase I/II study of Claudin 18.2 ADC ATG-022 in patients with advanced gastric/ gastroesophageal junction cancer (CLINCH)Abstract Number: 2907Presentation Number: 2113PDate: October 19, 2025 About ATG-022 ATG-022 is an antibody-drug conjugate (ADC) designed to target CLDN18.2, a member of the Claudin family of cell adhesion molecules. Under normal conditions, Claudins are located within tight junctions between cells, forming a barrier to regulate cell permeability. However, in cancer, Claudins are aberrantly expressed on the cell surface due to changes in cell polarity. CLDN18.2 is frequently overexpressed in a range of primary malignant tumors, including gastric, esophageal, cholangiocarcinoma, and pancreatic cancers. The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designations to ATG-022, for gastric and pancreatic cancers. Data from the ongoing CLINCH study demonstrated that ATG-022 delivers robust efficacy across all levels of CLDN18.2 expression in gastric cancer patients, including those with high, low, and ultra-low expression. This broad activity positions ATG-022 as a potential market leader, capable of addressing the largest patient population with CLDN18.2-positive tumors. Furthermore, the strong efficacy observed in patients with low CLDN18.2 expression suggests promise for treating other tumor types with similar expression profiles. About Antengene Antengene Corporation Limited ("Antengene", SEHK: is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact: Investor Contacts: Donald LungE-mail: Mobile: +86 18420672158 PR Contacts:Peter QianE-mail: Mobile: +86 13062747000 View original content to download multimedia: SOURCE Antengene Corporation Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
6 hours ago
- Associated Press
China proposes global cooperation body on AI
SHANGHAI, July 27, 2025 /PRNewswire/ -- A news report from The Chinese government has proposed the establishment of a world AI cooperation organization as part of its efforts to bolster open, inclusive and equitable artificial intelligence development and governance globally. Premier Li Qiang announced the initiative when addressing the opening ceremony of the 2025 World AI Conference and High-Level Meeting on Global AI Governance in Shanghai. Li emphasized the need for collaborative approaches to global AI governance to ensure that intelligent technologies are developed for the good of all. More than 1,000 high-level representatives from upwards of 40 countries and international organizations attended the opening ceremony of the three-day event, themed 'Global Solidarity in the AI Era'. Li said that the risks and challenges brought by AI development, such as machine hallucinations, deep fakes and AI proliferation, have aroused widespread attention. There is an urgent need to further consolidate a societal consensus on how to achieve a balance between development and security in the AI sector, he said. Li said greater emphasis should be placed on collective governance to ensure that AI ultimately benefits humanity. Given that global AI governance appears fragmented, it is essential to enhance coordination and alignment among countries around the world to establish a framework and rules for global AI governance with a broad consensus, he added. Noting that China places great importance on global AI governance and actively participates in promoting multilateral and bilateral cooperation in this regard, the premier said the nation is willing to offer more Chinese solutions to the international community and contribute more Chinese wisdom to global AI governance. In 2023, China proposed the Global AI Governance Initiative to promote an open, inclusive and fair approach to the development and governance of AI technologies. Last year, China proposed the AI Capacity-Building Action Plan for Good and for All to bridge the AI and digital divides, and to ensure the Global South benefits equitably from AI development. China actively promotes open source development, and is willing to collaborate with countries around the world to promote progress in software and hardware technologies, intensify open source initiatives, and collectively propel AI development to higher levels, Li said. Also on July 26, the conference adopted the Global AI Governance Action Plan, which calls on all parties to work in solidarity to advance AI development and governance. For more information: View original content to download multimedia: SOURCE
Yahoo
10 hours ago
- Yahoo
Magnetic Resources Joins 2 Other ASX Penny Stocks Worth Watching
The Australian market has experienced a mixed performance recently, with significant declines in materials and financials contrasted by gains in the energy sector. Despite these fluctuations, investors continue to seek opportunities beyond the major players, exploring areas like penny stocks for potential growth. While the term "penny stock" might seem outdated, these smaller or newer companies can still offer surprising value when backed by strong financials and stability. Top 10 Penny Stocks In Australia Name Share Price Market Cap Financial Health Rating Alfabs Australia (ASX:AAL) A$0.40 A$114.64M ★★★★☆☆ EZZ Life Science Holdings (ASX:EZZ) A$2.14 A$100.95M ★★★★★★ GTN (ASX:GTN) A$0.59 A$112.49M ★★★★★★ IVE Group (ASX:IGL) A$3.00 A$462.55M ★★★★★☆ West African Resources (ASX:WAF) A$2.38 A$2.71B ★★★★★★ Southern Cross Electrical Engineering (ASX:SXE) A$1.78 A$470.65M ★★★★★★ Regal Partners (ASX:RPL) A$2.90 A$975.05M ★★★★★★ Navigator Global Investments (ASX:NGI) A$1.815 A$889.49M ★★★★★☆ Austco Healthcare (ASX:AHC) A$0.38 A$138.44M ★★★★★★ CTI Logistics (ASX:CLX) A$1.86 A$149.81M ★★★★☆☆ Click here to see the full list of 464 stocks from our ASX Penny Stocks screener. Here's a peek at a few of the choices from the screener. Magnetic Resources Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Magnetic Resources NL is involved in the exploration of mineral tenements in Western Australia and has a market cap of A$411.91 million. Operations: Currently, there are no reported revenue segments for the company. Market Cap: A$411.91M Magnetic Resources NL, with a market cap of A$411.91 million, is currently pre-revenue and unprofitable, lacking significant revenue streams. The company has less than a year of cash runway based on its current free cash flow and no long-term liabilities or debt. Its short-term assets significantly surpass short-term liabilities, indicating sound financial management despite its challenges. Recent board changes include the appointment of Aaron Sim as an alternate director, bringing extensive financial advisory experience to the table. Earnings are forecast to grow significantly annually; however, past losses have increased over five years at 18.8% per year. Take a closer look at Magnetic Resources' potential here in our financial health report. Learn about Magnetic Resources' future growth trajectory here. NextEd Group Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: NextEd Group Limited offers educational services across Australia, Europe, and South America with a market cap of A$51.09 million. Operations: NextEd Group's revenue is primarily derived from its International Vocational segment at A$73.79 million, followed by Technology & Design at A$11.29 million, Domestic Vocational at A$9.22 million, and Go Study Group contributing A$6.16 million. Market Cap: A$51.09M NextEd Group Limited, with a market cap of A$51.09 million, primarily generates revenue from its International Vocational segment. Despite being unprofitable and not expected to achieve profitability in the next three years, it benefits from a strong cash runway exceeding three years due to positive free cash flow growth. The company is debt-free but faces challenges with short-term assets not covering liabilities. Recent leadership changes include appointing Andrew Nye as Chief Financial Officer, bringing extensive financial management expertise. Although NextEd trades at good value compared to peers, losses have increased significantly over the past five years. Dive into the specifics of NextEd Group here with our thorough balance sheet health report. Examine NextEd Group's earnings growth report to understand how analysts expect it to perform. Perenti Simply Wall St Financial Health Rating: ★★★★★★ Overview: Perenti Limited is a global mining services company with a market capitalization of A$1.64 billion. Operations: Perenti's revenue is primarily derived from Contract Mining Services at A$2.50 billion, followed by Drilling Services at A$750.65 million, and Mining Services and Idoba contributing A$229.77 million. Market Cap: A$1.64B Perenti Limited, with a market cap of A$1.64 billion, primarily derives revenue from Contract Mining Services (A$2.50 billion). Despite negative earnings growth over the past year and lower profit margins (2.5% compared to last year's 3.9%), the company is trading at a significant discount to its estimated fair value. Perenti's debt management has improved, with a reduced debt-to-equity ratio now at 45.5%, and its short-term assets exceed both short- and long-term liabilities, indicating solid financial footing. Earnings are forecasted to grow annually by 24.84%, supported by high-quality past earnings performance and stable weekly volatility (5%). Get an in-depth perspective on Perenti's performance by reading our balance sheet health report here. Evaluate Perenti's prospects by accessing our earnings growth report. Summing It All Up Jump into our full catalog of 464 ASX Penny Stocks here. Ready To Venture Into Other Investment Styles? AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:MAU ASX:NXD and ASX:PRN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data
